Top

Published in:

01-06-2014 | Original Article

Vascular Smooth Muscle Cells in Cerebral Aneurysm Pathogenesis

Authors: Robert M. Starke, Nohra Chalouhi, Dale Ding, Daniel M. S. Raper, M. Sean Mckisic, Gary K. Owens, David M. Hasan, Ricky Medel, Aaron S. Dumont

Published in: Translational Stroke Research | Issue 3/2014

Abstract

Vascular smooth muscle cells (SMC) maintain significant plasticity. Following environmental stimulation, SMC can alter their phenotype from one primarily concerned with contraction to a pro-inflammatory and matrix remodeling phenotype. This is a critical process behind peripheral vascular disease and atherosclerosis, a key element of cerebral aneurysm pathology. Evolving evidence demonstrates that SMCs and phenotypic modulation play a significant role in cerebral aneurysm formation and rupture. Pharmacological alteration of smooth muscle cell function and phenotypic modulation could provide a promising medical therapy to inhibit cerebral aneurysm progression. This study reviews vascular SMC function and its contribution to cerebral aneurysm pathophysiology.

Owens GK. Molecular control of vascular smooth muscle cell differentiation and phenotypic plasticity. Novartis Found Symp. 2007;283:174–91. discussion 91–3, 238–41.PubMedCrossRef

Alexander MR, Owens GK. Epigenetic control of smooth muscle cell differentiation and phenotypic switching in vascular development and disease. Annu Rev Physiol. 2012;74:13–40. doi:10.1146/annurev-physiol-012110-142315.PubMedCrossRef

Ali MS, Starke RM, Jabbour PM, Tjoumakaris SI, Gonzalez LF, Rosenwasser RH, et al. TNF-alpha induces phenotypic modulation in cerebral vascular smooth muscle cells: implications for cerebral aneurysm pathology. J Cereb Blood Flow Metab. 2013. doi:10.1038/jcbfm.2013.109.PubMed

Gomez D, Owens GK. Smooth muscle cell phenotypic switching in atherosclerosis. Cardiovasc Res. 2012;95(2):156–64. doi:10.1093/cvr/cvs115.PubMedCentralPubMedCrossRef

Owens GK, Kumar MS, Wamhoff BR. Molecular regulation of vascular smooth muscle cell differentiation in development and disease. Physiol Rev. 2004;84(3):767–801. doi:10.1152/physrev.00041.2003.PubMedCrossRef

Rinkel GJ. Natural history, epidemiology and screening of unruptured intracranial aneurysms. J Neuroradiol. 2008;35(2):99–103.PubMedCrossRef

Komotar RJ, Zacharia BE, Mocco J, Connolly Jr ES. Controversies in the surgical treatment of ruptured intracranial aneurysms: the First Annual J. Lawrence Pool Memorial Research Symposium—controversies in the management of cerebral aneurysms. Neurosurgery. 2008;62(2):396–407.PubMedCrossRef

van Gijn J, Kerr RS, Rinkel GJ. Subarachnoid haemorrhage. Lancet. 2007;369(9558):306–18.PubMedCrossRef

Kassell NF, Torner JC. The International Cooperative Study on Timing of Aneurysm Surgery—an update. Stroke. 1984;15(3):566–70.PubMedCrossRef

10.

Schievink WI. Intracranial aneurysms. N Engl J Med. 1997;336(1):28–40.PubMedCrossRef

11.

Ronkainen A, Miettinen H, Karkola K, Papinaho S, Vanninen R, Puranen M, et al. Risk of harboring an unruptured intracranial aneurysm. Stroke. 1998;29(2):359–62.PubMedCrossRef

12.

Laidlaw JD, Siu KH. Ultra-early surgery for aneurysmal subarachnoid hemorrhage: outcomes for a consecutive series of 391 patients not selected by grade or age. J Neurosurg. 2002;97(2):250–8. doi:10.3171/jns.2002.97.2.0250. discussion 47–9.PubMedCrossRef

13.

Hop JW, Rinkel GJ, Algra A, van Gijn J. Quality of life in patients and partners after aneurysmal subarachnoid hemorrhage. Stroke. 1998;29(4):798–804.PubMedCrossRef

14.

Ropper AH, Zervas NT. Outcome 1 year after SAH from cerebral aneurysm. Management morbidity, mortality, and functional status in 112 consecutive good-risk patients. J Neurosurg. 1984;60(5):909–15.PubMedCrossRef

15.

Nieuwkamp DJ, Setz LE, Algra A, Linn FH, de Rooij NK, Rinkel GJ. Changes in case fatality of aneurysmal subarachnoid haemorrhage over time, according to age, sex, and region: a meta-analysis. Lancet Neurol. 2009;8(7):635–42. doi:10.1016/S1474-4422(09)70126-7.PubMedCrossRef

16.

Rosenorn J, Eskesen V, Schmidt K, Espersen JO, Haase J, Harmsen A, et al. Clinical features and outcome in 1076 patients with ruptured intracranial saccular aneurysms: a prospective consecutive study. Br J Neurosurg. 1987;1(1):33–45.PubMedCrossRef

17.

Saveland H, Sonesson B, Ljunggren B, Brandt L, Uski T, Zygmunt S, et al. Outcome evaluation following subarachnoid hemorrhage. J Neurosurg. 1986;64(2):191–6.PubMedCrossRef

18.

Molyneux AJ, Kerr RS, Yu LM, Clarke M, Sneade M, Yarnold JA, et al. International subarachnoid aneurysm trial (ISAT) of neurosurgical clipping versus endovascular coiling in 2143 patients with ruptured intracranial aneurysms: a randomised comparison of effects on survival, dependency, seizures, rebleeding, subgroups, and aneurysm occlusion. Lancet. 2005;366(9488):809–17. doi:10.1016/S0140-6736(05)67214-5.PubMedCrossRef

19.

Wiebers DO, Whisnant JP, Huston 3rd J, Meissner I, Brown Jr RD, Piepgras DG, et al. Unruptured intracranial aneurysms: natural history, clinical outcome, and risks of surgical and endovascular treatment. Lancet. 2003;362(9378):103–10.PubMedCrossRef

20.

Chalouhi N, Ali MS, Jabbour PM, Tjoumakaris SI, Gonzalez LF, Rosenwasser RH, et al. Biology of intracranial aneurysms: role of inflammation. J Cereb Blood Flow Metab. 2012;32(9):1659–76. doi:10.1038/jcbfm.2012.84.PubMedCentralPubMedCrossRef

21.

Hungerford JE, Little CD. Developmental biology of the vascular smooth muscle cell: building a multilayered vessel wall. J Vasc Res. 1999;36(1):2–27.PubMedCrossRef

22.

Gabbiani G, Schmid E, Winter S, Chaponnier C, de Ckhastonay C, Vandekerckhove J, et al. Vascular smooth muscle cells differ from other smooth muscle cells: predominance of vimentin filaments and a specific alpha-type actin. Proc Natl Acad Sci U S A. 1981;78(1):298–302.PubMedCentralPubMedCrossRef

23.

Babij P, Kelly C, Periasamy M. Characterization of a mammalian smooth muscle myosin heavy-chain gene: complete nucleotide and protein coding sequence and analysis of the 5′ end of the gene. Proc Natl Acad Sci U S A. 1991;88(23):10676–80.PubMedCentralPubMedCrossRef

24.

Duband JL, Gimona M, Scatena M, Sartore S, Small JV. Calponin and SM 22 as differentiation markers of smooth muscle: spatiotemporal distribution during avian embryonic development. Differentiation. 1993;55(1):1–11.PubMedCrossRef

25.

van der Loop FT, Schaart G, Timmer ED, Ramaekers FC, van Eys GJ. Smoothelin, a novel cytoskeletal protein specific for smooth muscle cells. J Cell Biol. 1996;134(2):401–11.PubMedCrossRef

26.

Li L, Miano JM, Cserjesi P, Olson EN. SM22 alpha, a marker of adult smooth muscle, is expressed in multiple myogenic lineages during embryogenesis. Circ Res. 1996;78(2):188–95.PubMedCrossRef

27.

Caplice NM, Bunch TJ, Stalboerger PG, Wang S, Simper D, Miller DV, et al. Smooth muscle cells in human coronary atherosclerosis can originate from cells administered at marrow transplantation. Proc Natl Acad Sci U S A. 2003;100(8):4754–9. doi:10.1073/pnas.0730743100.PubMedCentralPubMedCrossRef

28.

Stewart HJ, Guildford AL, Lawrence-Watt DJ, Santin M. Substrate-induced phenotypical change of monocytes/macrophages into myofibroblast-like cells: a new insight into the mechanism of in-stent restenosis. J Biomed Mater Res A. 2009;90(2):465–71. doi:10.1002/jbm.a.32100.PubMedCrossRef

29.

Martin K, Weiss S, Metharom P, Schmeckpeper J, Hynes B, O’Sullivan J, et al. Thrombin stimulates smooth muscle cell differentiation from peripheral blood mononuclear cells via protease-activated receptor-1, RhoA, and myocardin. Circ Res. 2009;105(3):214–8. doi:10.1161/CIRCRESAHA.109.199984.PubMedCrossRef

30.

Andreeva ER, Pugach IM, Orekhov AN. Subendothelial smooth muscle cells of human aorta express macrophage antigen in situ and in vitro. Atherosclerosis. 1997;135(1):19–27.PubMedCrossRef

31.

Rong JX, Shapiro M, Trogan E, Fisher EA. Transdifferentiation of mouse aortic smooth muscle cells to a macrophage-like state after cholesterol loading. Proc Natl Acad Sci U S A. 2003;100(23):13531–6. doi:10.1073/pnas.1735526100.PubMedCentralPubMedCrossRef

32.

Gomez D, Owens GK. Smooth muscle cell phenotypic switching in atherosclerosis. Cardiovasc Res. 2012. doi:10.1093/cvr/cvs115.

33.

Lee RT, Libby P. The unstable atheroma. Arterioscler Thromb Vasc Biol. 1997;17(10):1859–67.PubMedCrossRef

34.

Falk E. Why do plaques rupture? Circulation. 1992;86(6 Suppl):III30–42.PubMed

35.

Owens GK. Molecular control of vascular smooth muscle cell differentiation. Acta Physiol Scand. 1998;164(4):623–35.PubMed

36.

McDonald OG, Wamhoff BR, Hoofnagle MH, Owens GK. Control of SRF binding to CArG box chromatin regulates smooth muscle gene expression in vivo. J Clin Invest. 2006;116(1):36–48. doi:10.1172/JCI26505.PubMedCentralPubMedCrossRef

37.

Sano H, Sudo T, Yokode M, Murayama T, Kataoka H, Takakura N, et al. Functional blockade of platelet-derived growth factor receptor-beta but not of receptor-alpha prevents vascular smooth muscle cell accumulation in fibrous cap lesions in apolipoprotein E-deficient mice. Circulation. 2001;103(24):2955–60.PubMedCrossRef

38.

Jawien A, Bowen-Pope DF, Lindner V, Schwartz SM, Clowes AW. Platelet-derived growth factor promotes smooth muscle migration and intimal thickening in a rat model of balloon angioplasty. J Clin Invest. 1992;89(2):507–11. doi:10.1172/JCI115613.PubMedCentralPubMedCrossRef

39.

Amento EP, Ehsani N, Palmer H, Libby P. Cytokines and growth factors positively and negatively regulate interstitial collagen gene expression in human vascular smooth muscle cells. Arterioscler Thromb. 1991;11(5):1223–30.PubMedCrossRef

40.

Johnstone SR, Ross J, Rizzo MJ, Straub AC, Lampe PD, Leitinger N, et al. Oxidized phospholipid species promote in vivo differential cx43 phosphorylation and vascular smooth muscle cell proliferation. Am J Pathol. 2009;175(2):916–24. doi:10.2353/ajpath.2009.090160.PubMedCentralPubMedCrossRef

41.

Couffinhal T, Duplaa C, Moreau C, Lamaziere JM, Bonnet J. Regulation of vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 in human vascular smooth muscle cells. Circ Res. 1994;74(2):225–34.PubMedCrossRef

42.

Loppnow H, Libby P. Proliferating or interleukin 1-activated human vascular smooth muscle cells secrete copious interleukin 6. J Clin Invest. 1990;85(3):731–8. doi:10.1172/JCI114498.PubMedCentralPubMedCrossRef

43.

Fabunmi RP, Baker AH, Murray EJ, Booth RF, Newby AC. Divergent regulation by growth factors and cytokines of 95 kDa and 72 kDa gelatinases and tissue inhibitors or metalloproteinases-1, −2, and −3 in rabbit aortic smooth muscle cells. Biochem J. 1996;315(Pt 1):335–42.PubMedCentralPubMed

44.

Speer MY, Yang HY, Brabb T, Leaf E, Look A, Lin WL, et al. Smooth muscle cells give rise to osteochondrogenic precursors and chondrocytes in calcifying arteries. Circ Res. 2009;104(6):733–41. doi:10.1161/CIRCRESAHA.108.183053.PubMedCentralPubMedCrossRef

45.

Jiang J, Chan YS, Loh YH, Cai J, Tong GQ, Lim CA, et al. A core Klf circuitry regulates self-renewal of embryonic stem cells. Nat Cell Biol. 2008;10(3):353–60. doi:10.1038/ncb1698.PubMedCrossRef

46.

Wernig M, Meissner A, Foreman R, Brambrink T, Ku M, Hochedlinger K, et al. In vitro reprogramming of fibroblasts into a pluripotent ES-cell-like state. Nature. 2007;448(7151):318–24. doi:10.1038/nature05944.PubMedCrossRef

47.

Yoshida T, Kaestner KH, Owens GK. Conditional deletion of Kruppel-like factor 4 delays downregulation of smooth muscle cell differentiation markers but accelerates neointimal formation following vascular injury. Circ Res. 2008;102(12):1548–57. doi:10.1161/CIRCRESAHA.108.176974.PubMedCentralPubMedCrossRef

48.

Wamhoff BR, Hoofnagle MH, Burns A, Sinha S, McDonald OG, Owens GK. A G/C element mediates repression of the SM22alpha promoter within phenotypically modulated smooth muscle cells in experimental atherosclerosis. Circ Res. 2004;95(10):981–8. doi:10.1161/01.RES.0000147961.09840.fb.PubMedCrossRef

49.

Salmon M, Gomez D, Greene E, Shankman L, Owens GK. Cooperative binding of KLF4, pELK-1, and HDAC2 to a G/C repressor element in the SM22alpha promoter mediates transcriptional silencing during SMC phenotypic switching in vivo. Circ Res. 2012;111(6):685–96. doi:10.1161/CIRCRESAHA.112.269811.PubMedCentralPubMedCrossRef

50.

Starke RM, Chalouhi N, Ali MS, Jabbour PM, Tjoumakaris SI, Gonzalez LF, et al. The role of oxidative stress in cerebral aneurysm formation and rupture. Curr Neurovasc Res. 2013;10(3):247–55.PubMedCentralPubMedCrossRef

51.

Alfano JM, Kolega J, Natarajan SK, Xiang J, Paluch RA, Levy EI, et al. Intracranial aneurysms occur more frequently at bifurcation sites that typically experience higher hemodynamic stresses. Neurosurgery. 2013. doi:10.1227/NEU.0000000000000016.PubMed

52.

Kolega J, Gao L, Mandelbaum M, Mocco J, Siddiqui AH, Natarajan SK, et al. Cellular and molecular responses of the basilar terminus to hemodynamics during intracranial aneurysm initiation in a rabbit model. J Vasc Res. 2011;48(5):429–42. doi:10.1159/000324840.PubMedCentralPubMedCrossRef

53.

Aoki T, Kataoka H, Nishimura M, Ishibashi R, Morishita R, Miyamoto S. Ets-1 promotes the progression of cerebral aneurysm by inducing the expression of MCP-1 in vascular smooth muscle cells. Gene Ther. 2010;17(9):1117–23. doi:10.1038/gt.2010.60.PubMedCrossRef

54.

Bygglin H, Laaksamo E, Myllarniemi M, Tulamo R, Hernesniemi J, Niemela M, et al. Isolation, culture, and characterization of smooth muscle cells from human intracranial aneurysms. Acta Neurochir (Wien). 2011;153(2):311–8. doi:10.1007/s00701-010-0836-x.PubMedCrossRef

55.

Chalouhi N, Ali MS, Starke RM, Jabbour PM, Tjoumakaris SI, Gonzalez LF, et al. Cigarette smoke and inflammation: role in cerebral aneurysm formation and rupture. Mediators Inflamm. 2012;2012:271582. doi:10.1155/2012/271582.PubMedCentralPubMed

56.

Kosierkiewicz TA, Factor SM, Dickson DW. Immunocytochemical studies of atherosclerotic lesions of cerebral berry aneurysms. J Neuropathol Exp Neurol. 1994;53(4):399–406.PubMedCrossRef

57.

Frosen J, Marjamaa J, Myllarniemi M, Abo-Ramadan U, Tulamo R, Niemela M, et al. Contribution of mural and bone marrow-derived neointimal cells to thrombus organization and wall remodeling in a microsurgical murine saccular aneurysm model. Neurosurgery. 2006;58(5):936–44. doi:10.1227/01.NEU.0000210260.55124.A4. discussion −44.PubMedCrossRef

58.

Starke RM, Ali M, Jabbour P, Tjoumakaris SI, Gonzalez LF, Hasan D, et al. Cigarette smoke modulates vascular smooth muscle phenotype: implications for carotid and cerebrovascular disease. Plos One. 2013;8(8):e71954. doi:10.1371/journal.pone.0071954.PubMedCentralPubMedCrossRef

59.

Nakajima N, Nagahiro S, Sano T, Satomi J, Satoh K. Phenotypic modulation of smooth muscle cells in human cerebral aneurysmal walls. Acta Neuropathol. 2000;100(5):475–80.PubMedCrossRef

60.

Kilic T, Sohrabifar M, Kurtkaya O, Yildirim O, Elmaci I, Gunel M, et al. Expression of structural proteins and angiogenic factors in normal arterial and unruptured and ruptured aneurysm walls. Neurosurgery. 2005;57(5):997–1007. discussion 997.PubMedCrossRef

61.

Pera J, Korostynski M, Krzyszkowski T, Czopek J, Slowik A, Dziedzic T, et al. Gene expression profiles in human ruptured and unruptured intracranial aneurysms: what is the role of inflammation? Stroke. 2010;41(2):224–31. doi:10.1161/STROKEAHA.109.562009.PubMedCrossRef

62.

Sibon I, Mercier N, Darret D, Lacolley P, Lamaziere JM. Association between semicarbazide-sensitive amine oxidase, a regulator of the glucose transporter, and elastic lamellae thinning during experimental cerebral aneurysm development: laboratory investigation. J Neurosurg. 2008;108(3):558–66. doi:10.3171/jns/2008/108/3/0558.PubMedCrossRef

63.

Merei FT, Gallyas F. Role of the structural elements of the arterial wall in the formation and growth of intracranial saccular aneurysms. Neurol Res. 1980;2(3–4):283–303.PubMed

64.

Coucke PJ, Willaert A, Wessels MW, Callewaert B, Zoppi N, De Backer J, et al. Mutations in the facilitative glucose transporter GLUT10 alter angiogenesis and cause arterial tortuosity syndrome. Nat Genet. 2006;38(4):452–7. doi:10.1038/ng1764.PubMedCrossRef

65.

Ali MS, Starke RM, Jabbour P, Tjoumakaris SI, Gonzalez LF, Rosenwasser RH, et al. 184 Infliximab suppresses TNF-alpha induced inflammatory phenotype in cerebral vascular smooth muscle cells: implications for cerebral aneurysm formation. Neurosurgery. 2013;60 Suppl 1:181. doi:10.1227/01.neu.0000432774.35977.11.CrossRef

66.

Chalouhi N, Points L, Pierce GL, Ballas Z, Jabbour P, Hasan D. Localized increase of chemokines in the lumen of human cerebral aneurysms. Stroke. 2013. doi:10.1161/STROKEAHA.113.002361.

67.

Aoki T, Kataoka H, Ishibashi R, Nozaki K, Egashira K, Hashimoto N. Impact of monocyte chemoattractant protein-1 deficiency on cerebral aneurysm formation. Stroke. 2009;40(3):942–51. doi:10.1161/STROKEAHA.108.532556.PubMedCrossRef

68.

Aoki T, Kataoka H, Ishibashi R, Nozaki K, Morishita R, Hashimoto N. Reduced collagen biosynthesis is the hallmark of cerebral aneurysm: contribution of interleukin-1beta and nuclear factor-kappaB. Arterioscler Thromb Vasc Biol. 2009;29(7):1080–6. doi:10.1161/ATVBAHA.108.180760.PubMedCrossRef

69.

Aoki T, Kataoka H, Shimamura M, Nakagami H, Wakayama K, Moriwaki T, et al. NF-kappaB is a key mediator of cerebral aneurysm formation. Circulation. 2007;116(24):2830–40. doi:10.1161/CIRCULATIONAHA.107.728303.PubMedCrossRef

70.

Kim SC, Singh M, Huang J, Prestigiacomo CJ, Winfree CJ, Solomon RA, et al. Matrix metalloproteinase-9 in cerebral aneurysms. Neurosurgery. 1997;41(3):642–66. discussion 6–7.PubMed

71.

Aoki T, Kataoka H, Morimoto M, Nozaki K, Hashimoto N. Macrophage-derived matrix metalloproteinase-2 and -9 promote the progression of cerebral aneurysms in rats. Stroke. 2007;38(1):162–9. doi:10.1161/01.STR.0000252129.18605.c8.PubMedCrossRef

72.

Moriwaki T, Takagi Y, Sadamasa N, Aoki T, Nozaki K, Hashimoto N. Impaired progression of cerebral aneurysms in interleukin-1beta-deficient mice. Stroke. 2006;37(3):900–5. doi:10.1161/01.STR.0000204028.39783.d9.PubMedCrossRef

73.

Fukuda S, Hashimoto N, Naritomi H, Nagata I, Nozaki K, Kondo S, et al. Prevention of rat cerebral aneurysm formation by inhibition of nitric oxide synthase. Circulation. 2000;101(21):2532–8.PubMedCrossRef

74.

Jayaraman T, Berenstein V, Li X, Mayer J, Silane M, Shin YS, et al. Tumor necrosis factor alpha is a key modulator of inflammation in cerebral aneurysms. Neurosurgery. 2005;57(3):558–64. discussion −64.PubMedCrossRef

75.

Sakaki T, Kohmura E, Kishiguchi T, Yuguchi T, Yamashita T, Hayakawa T. Loss and apoptosis of smooth muscle cells in intracranial aneurysms. Studies with in situ DNA end labeling and antibody against single-stranded DNA. Acta Neurochir (Wien). 1997;139(5):469–74.CrossRef

76.

Hara A, Yoshimi N, Mori H. Evidence for apoptosis in human intracranial aneurysms. Neurol Res. 1998;20(2):127–30.PubMed

77.

Guo F, Li Z, Song L, Han T, Feng Q, Guo Y, et al. Increased apoptosis and cysteinyl aspartate specific protease-3 gene expression in human intracranial aneurysm. J Clin Neurosci. 2007;14(6):550–5. doi:10.1016/j.jocn.2005.11.018.PubMedCrossRef

78.

Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;131(5):861–72. doi:10.1016/j.cell.2007.11.019.PubMedCrossRef

79.

Frosen J, Tulamo R, Paetau A, Laaksamo E, Korja M, Laakso A, et al. Saccular intracranial aneurysm: pathology and mechanisms. Acta Neuropathol. 2012;123(6):773–86. doi:10.1007/s00401-011-0939-3.PubMedCrossRef

80.

Vlak MH, Algra A, Brandenburg R, Rinkel GJ. Prevalence of unruptured intracranial aneurysms, with emphasis on sex, age, comorbidity, country, and time period: a systematic review and meta-analysis. Lancet Neurol. 2011;10(7):626–36. doi:10.1016/S1474-4422(11)70109-0.PubMedCrossRef

81.

Vlak MH, Rinkel GJ, Greebe P, Algra A. Independent risk factors for intracranial aneurysms and their joint effect: a case–control study. Stroke. 2013;44(4):984–7. doi:10.1161/STROKEAHA.111.000329.PubMedCrossRef

82.

Gerzanich V, Zhang F, West GA, Simard JM. Chronic nicotine alters NO signaling of Ca(2+) channels in cerebral arterioles. Circ Res. 2001;88(3):359–65.PubMedCrossRef

83.

Starke RM, Chalouhi N, Ali MS, Jabbour P, Tjoumakaris SI, Gonzalez LF, et al. 190 critical role of TNF-a in cerebral aneurysm formation and rupture. Neurosurgery. 2013;60 Suppl 1:183. doi:10.1227/01.neu.0000432780.74094.e2.CrossRef

84.

Faustman D, Davis M. TNF receptor 2 pathway: drug target for autoimmune diseases. Nat Rev Drug Discov. 2010;9(6):482–93. doi:10.1038/nrd3030.PubMedCrossRef

85.

Bonilla-Hernan MG, Miranda-Carus ME, Martin-Mola E. New drugs beyond biologics in rheumatoid arthritis: the kinase inhibitors. Rheumatology (Oxford). 2013;50(9):1542–50. doi:10.1093/rheumatology/ker192.CrossRef

86.

Hasan D, Chalouhi N, Jabbour P, Dumont AS, Kung DK, Magnotta VA, et al. Early change in ferumoxytol-enhanced magnetic resonance imaging signal suggests unstable human cerebral aneurysm: a pilot study. Stroke. 2012;43(12):3258–65. doi:10.1161/STROKEAHA.112.673400.PubMedCentralPubMedCrossRef

87.

Hasan DM, Chalouhi N, Jabbour P, Dumont AS, Kung DK, Magnotta VA, et al. Evidence that acetylsalicylic acid attenuates inflammation in the walls of human cerebral aneurysms: preliminary results. J Am Heart Assoc. 2013;2(1):e000019. doi:10.1161/JAHA.112.000019.PubMedCentralPubMedCrossRef

88.

Hasan DM, Chalouhi N, Jabbour P, Magnotta VA, Kung DK, Young WL. Imaging aspirin effect on macrophages in the wall of human cerebral aneurysms using ferumoxytol-enhanced MRI: preliminary results. J Neuroradiol. 2013;40(3):187–91. doi:10.1016/j.neurad.2012.09.002.PubMedCrossRef

89.

Hasan DM, Mahaney KB, Magnotta VA, Kung DK, Lawton MT, Hashimoto T, et al. Macrophage imaging within human cerebral aneurysms wall using ferumoxytol-enhanced MRI: a pilot study. Arterioscler Thromb Vasc Biol. 2012;32(4):1032–8. doi:10.1161/ATVBAHA.111.239871.PubMedCentralPubMedCrossRef

Title: Vascular Smooth Muscle Cells in Cerebral Aneurysm Pathogenesis
Authors: Robert M. Starke
Nohra Chalouhi
Dale Ding
Daniel M. S. Raper
M. Sean Mckisic
Gary K. Owens
David M. Hasan
Ricky Medel
Aaron S. Dumont
Publication date: 01-06-2014
Publisher: Springer US
Published in: Translational Stroke Research / Issue 3/2014
Print ISSN: 1868-4483
Electronic ISSN: 1868-601X
DOI: https://doi.org/10.1007/s12975-013-0290-1

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Vascular Smooth Muscle Cells in Cerebral Aneurysm Pathogenesis

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2014

Catheter Placement for Lysis of Spontaneous Intracerebral Hematomas: Is a Navigated Stylet Better Than Pointer-Guided Frameless Stereotaxy for Intrahematomal Catheter Positioning?

Plasticity of Cerebrovascular Smooth Muscle Cells After Subarachnoid Hemorrhage

Intracerebral Hemorrhage: A Multimodality Approach to Improving Outcome

Brain Arteriovenous Malformation Modeling, Pathogenesis, and Novel Therapeutic Targets

Smooth Muscle Cells and the Formation, Degeneration, and Rupture of Saccular Intracranial Aneurysm Wall—a Review of Current Pathophysiological Knowledge

Alzheimer’s Silent Partner: Cerebral Amyloid Angiopathy